Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 41 of 101, showing 5 Applications out of 502 total, starting on record 201, ending on 205

# Protocol No Study Title Investigator(s) & Site(s)

201.

ECCT/13/07/01   HIVCORE004/N004
    A phase I/IIa clinical trial of universal HIV-1 vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and ChAdV63.HIVconsv in combined regimens in healthy HIV-1/2-negative adults in Nairobi.   
Principal Investigator(s)
1. Prof. Walter Godfrey Jaoko
Site(s) in Kenya
KAVI-KANGEMI RESEARCH SITE
 
View

202.

ECCT/23/10/02   MATRIX-001 protocol
    A Phase I Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Pharmacokinetics, and Modeled Pharmacodynamics of a Vaginal Insert Containing Tenofovir Alafenamide and Elvitegravir       
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD Thika
 
View

203.

ECCT/24/10/05   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
View

204.

ECCT/24/10/04   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project Clinical Research Centre (Kericho county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Aga Khan University Hospital Nairobi (Nairobi City county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
View

205.

ECCT/24/07/02   TMC278LAHTX4002
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studies   
Principal Investigator(s)
1. Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho, Kenya (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Nairobi City county)
 
View